about
sameAs
A Parp Inhibitor (BMN 673) for Inoperable Advanced eNDometrial cAncerPilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA MutationsA Study of Talazoparib in Patients With Advanced Solid TumorsAvelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100)A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid TumorsComparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid TumorsA Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid TumorsGedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast CancersTalazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung CancerA Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast CancerStudy of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological MalignanciesStudy of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid TumorsStudy of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid TumorsTalazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPCI-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerJavelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid TumorsTalazoparib, Carboplatin, and Paclitaxel in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryStudy of the PARP Inhibitor BMN 673 in Advanced Cancer Patients With Somatic Alterations in BRCA1/2, Mutations/Deletions in PTEN or PTEN Loss, a Homologous Recombination Defect, Mutations/Deletions in Other BRCA Pathway Genes and Germline MutatiA Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)Talazoparib For Neoadjuvant Treatment Of Germline Brca1/2 Mutation Patients With Early Triple-negative Breast CancerA Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid TumorsPARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid TumorsTalazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid MalignanciesPhase II Talazoparib in BRCA1 +BRCA2 Wild-Type &Triple-Neg /HER2-Negative Breast Cancer /SolidTumorsNeoadjuvant Talazoparib for Patients With a BRCA Deleterious MutationStudy of BMN 673, a PARP Inhibitor, in Healthy Adult Male VolunteersLung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung CancerTalazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid TumorsStudy of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast CancerBMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor TreatmentTalazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal CancerLung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung CancerTalazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent MalignanciesA Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate CancerA Study of the Drugs Talazoparib and Temozolomide in Prostate CancerEvaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical TrialTalazoparib for Cohesin-Mutated AML and MDS With Excess BlastsTalazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic CancersTALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer
P4844
Q61894657-C5E714F6-7D3E-4D67-9A17-076E0CE507C1Q61970165-E59069C5-3F4C-420F-B6FD-3E6278B19485Q63229093-701E699F-893C-4FB2-BB30-A0ECAE98824EQ63393796-83C117ED-E85B-49B4-8F8C-934E1018252EQ63393925-9F1F4771-5C24-4298-86D1-2809AC27A5D1Q63401540-1DADA9E7-5B9F-4CDE-889C-84B68855E7CDQ63572233-67D3BE5A-21E6-431D-B3A6-299A13B0025CQ63575185-DFF8B031-EFA3-4399-AAE5-6F2A2FC00BBAQ63579100-887CE269-B9A3-413E-B178-AD499553DDADQ63598049-11F1D490-EABC-428B-955C-1DCF52BD1D4EQ63805819-CE7FE067-34E2-41FD-A1DC-2BB36FE24C52Q63807417-53219F8C-4737-47AA-8282-482C6C7C0CDCQ63808603-F40B612A-F04C-4FC6-B6AB-B177C03E9FDDQ63814434-36299E54-BE42-4111-AC7A-C9BE3DFC0DB1Q64121488-C2003C09-A605-45CB-8DCB-D7C7E8EB36ECQ64123636-DB1F0EC0-F8EF-46B7-97FB-164896586FC9Q64150497-15D8957D-E1AD-489D-94BB-B23CFAF0ECB7Q64151744-6BDEF755-8481-41FB-BD2E-63023A6AC8B3Q64151768-DC1DABA3-030E-4C6C-A2B8-CFEABEF65D5FQ64183826-33F3FA76-F82D-43D2-9DBA-6D5CA4A5153EQ64187738-E96498FE-FE83-4552-BC53-221D1AF1E3A6Q64187844-849503B1-CA6A-489C-9ED8-B170387472DBQ64336937-A5618148-FA85-4224-851B-C98C759A470CQ64376518-8D7EB994-4B52-49CA-A59C-E780B623D5D4Q64394350-834FCEA2-F606-434F-AC04-451F9EA8E43DQ64625495-55DC92EF-70CD-400B-A01A-8E45A61DD3B6Q64635712-E57220EF-030D-4CB5-B314-BE238C7A7391Q64806376-05241145-271C-4B31-99C0-1A90D2690041Q65332646-32AD7970-38E2-4053-93C7-525442C53893Q65349100-A18D5FEF-FB53-49F1-9ABC-06728C8E2788Q65351336-3974961B-5F36-4F99-B37F-9AF83002E025Q65354626-7E09F5D6-67EF-46D4-A375-D1C57B9B06ABQ65355788-C97E6518-29CE-49E5-8C33-F5A145C61F7AQ65357400-419997E1-B5A2-4E53-B254-9639114F6484Q66044609-18166939-F65D-441C-AE9F-47E601C61C9BQ66061659-C8056B10-B09E-4387-B0B0-63B22E315ABEQ66064086-F031BAAA-700A-4454-867E-D1BC8B3477FEQ66064650-389A955E-E88F-454B-9777-A6E73FD01147Q66065590-89EE6E76-6EA1-4F2E-87C1-D8099FDFD97FQ66066199-F54B16E9-62AC-4665-88C8-A40C2ADDABC8
P4844
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Talazoparib
@en
type
label
Talazoparib
@en
altLabel
BMN-673
@en
talazoparib
@en
prefLabel
Talazoparib
@en
P6366
P661
P662
P117
P2017
CN1C(=NC=N1)[C@@H]2[C@H](N=C3C=C(C=C4C3=C2NNC4=O)F)C5=CC=C(C=C5)F
P2067
380.119716
P233
CN1C(=NC=N1)C2C(N=C3C=C(C=C4C3=C2NNC4=O)F)C5=CC=C(C=C5)F
P234
1S/C19H14F2N6O/c1-27-18(22-8-2 ...... H,1H3,(H,26,28)/t15-,16-/m1/s1
P235
IUEWAGVJRJORLA-HZPDHXFCSA-N
P267
P274
C₁₉H₁₄F₂N₆O
P6366
2776771940
P661
P662
P7830
Talazoparib